Chlormethine Gel for the Treatment of Mycosis Fungoides (Cutaneous T-cell Lymphoma) in Canada.
Skin Therapy Lett
; 28(2): 1-5, 2023 Mar.
Article
em En
| MEDLINE
| ID: mdl-37054720
ABSTRACT
Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), representing almost 50% of all lymphomas arising in the skin. There is an unmet need in the treatment of MF in Canada, as current available therapies for early-stage MF are limited, without topical agents previously indicated. Chlormethine gel is a topical antineoplastic agent with phase II clinical trial and real-world data demonstrating safety and efficacy as a treatment option for adults with MF. Skin-related side effects such as dermatitis can be managed through appropriate strategies. The use of chlormethine gel can be considered for patients with stage IA and IB MF-CTCL as it provides an easily administered, skin-directed treatment option that fills an unmet need in Canada.
Palavras-chave
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Cutâneas
/
Linfoma Cutâneo de Células T
/
Micose Fungoide
Limite:
Adult
/
Humans
Idioma:
En
Revista:
Skin Therapy Lett
Assunto da revista:
DERMATOLOGIA
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Canadá